Canine Papillamatozisde Bleomisinin Klinik Etkinliği: İki Yavru Kardeş Köpeğin Olgu Sunumu

Yıl 2024, Cilt: 5 Sayı: 1, 18 - 22, 28.06.2024

Songül Erdoğan , Gözde Ak , Hasan Erdoğan , Kerem Ural

https://doi.org/10.58833/bozokvetsci.1425583

Öz

Amaç: Amaç anti-tümoral bleomisinin iki erkek, Pug ırkı yavru kardeş köpekde canine papillamatozis (CP) üzerine klinik etkinliğinin değerlendirilmesidir.
Materyal ve Yöntem: İki tane 8 aylık yaşta, erkek yavru kardeş köpek ağız ve çene bölgesinde birden fazla siğil lezyonu ile başvuruda bulundu. Şüpheli canine papillamatozis tanısı yalnızca tipik karnıbahar benzeri siğil görüntüsünü içeren klinik bulgular ile konuldu. Her iki kardeşte bleomisin haftalık 0.5 IU/kg dozda deri altı yolla uygulandı.
Bulgular: 6. haftada kardeşlerden birinde oral lezyonlar tamamen kaybolurken diğer kardeşte tam iyileşme 9. haftada sağlandı. Siğiller yeni lezyon olmaksızın kalıcı olarak tamamen çözüldü. Haftalık kan sayımı ve fiziksel muayene bulgularıyla takip yapıldı ve tedavi süresince ve sonrasında hiçbir yan etki görülmedi.
Sonuç: Deri altı yolla 0.5 IU/kg dozda haftalık uygulanan köpeklerde oral lezyonların gerilemesine ve klinik sonuçların iyileşmesine katkıda bulunması bleomisinin CP tedavisinde potansiyel etkinliğini desteklemektedir.
Anahtar Kelimeler: bleomisin, oral lezyon, papilloma, siğiller.

Anahtar Kelimeler

bleomisin, oral lezyon, papilloma, siğiller

Etik Beyan

-

Destekleyen Kurum

-

Teşekkür

-

Clinical Efficacy of Bleomycin in Canine Papillomatosis: Case Report of Two Sibling Puppies

Öz

Aim: The objective was to assess the clinical efficacy of anti-tumoral bleomycin on canine papillomatosis (CP) in two male Pug breed sibling puppies.
Material and Methods: Two 8 month-old, male sibling puppies were presented with multiple warts in the lip and chin. A suspected diagnosis of CP was established through only clinical examination with appearance of typical cauliflower-like warts. Bleomycin was subcutaneously administered to both siblings on a weekly by 0.5 IU/kg dosage.
Results: At week 6, one of the siblings exhibited complete regression of oral lesions, whereas the other sibling achieved complete healing by week 9. The warts persistently show complete resolution, with no new lesions. No adverse effects were observed, verified through weekly blood count and physical examination during and post-treatment.
Conclusion: Subcutaneous administration of bleomycin at weekly at a dose of 0.5 IU/kg contributed to the regression of oral lesions and improved clinical outcomes in dogs, suggesting potential efficiency in the treatment of CP.

Anahtar Kelimeler

bleomycin, oral lesion, papilloma, warts

Kaynakça

• 1. Cruz-Gregorio A, Aranda-Rivera AK, Pedraza-Chaverri J. Pathological similarities in the development of papillomavirus-associated cancer in humans, dogs, and cats. Animals 2022; 12(18): 2390.
• 2. Munday JS, Gedye K, Knox MA, Ravens P, Lin X. Genomic characterization of Canis familiaris papillomavirus type 24, a novel papillomavirus associated with extensive pigmented plaque formation in a Pug dog. Viruses 2022; 14(11): 2357.
• 3. Chang CY, Chen WT, Haga T, Yamashita N, Lee CF, et al. The detection and association of canine papillomavirus with benign and malignant skin lesions in dogs. Viruses 2020; 12(2): 170.
• 4. Alves CD, Weber MN, Guimarães LL, Cibulski SP, et al. Canine papillomavirus type 16 associated to squamous cell carcinoma in a dog: Virological and pathological findings. Brazilian Journal of Microbiology 2020; 51: 2087-2094.
• 5. Lane HE, Weese JS, Stull JW. Canine oral papillomavirus outbreak at a dog daycare facility. The Canadian Veterinary Journal 2017; 58(7): 747.
• 6. Sancak A, Favrot C, Geisseler MD, Müller M, Lange CE. Antibody titres against canine papillomavirus 1 peak around clinical regression in naturally occurring oral papillomatosis. Veterinary Dermatology 2015; 26(1): 57-e20.
• 7. Munday JS, Thomson NA, Luff JA. Papillomaviruses in dogs and cats. The Veterinary Journal 2017; 225: 23-31.
• 8. Rich N, Duclos D, Yuan H. Management of severe, progressive oral papillomatosis in a dog with CO2 laser ablation and canine papillomavirus L1 immunisation. Veterinary Record Case Reports 2021; 9(4): e168.
• 9. Sharun K, Kalaiselva E, Sindhoora K, Faslu Rahman AT, Azam Khan AM.et al. Oral papillomatosis in a dog: Surgical management and histopathological findings. Advances in Animal and Veterinary Sciences 2020; 8(4): 408-411. Doi:10.17582/journal.aavs/2020/8.4.408.411.
• 10. Yaǧcı BB, Ural K, Öcal N, Haydardedeoǧlu AE. Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double‐blinded, placebo‐controlled clinical trial. Veterinary Dermatology 2008; 19(4): 194-198.
• 11. Regalado Ibarra AM, Legendre L, Munday JS. Malignant transformation of a canine papillomavirus type 1-induced persistent oral papilloma in a 3-year-old dog. Journal of Veterinary Dentistry 2018; 35(2): 79-95.
• 12. Ibarra R. Analysis of Clinical Efficacy of Intralesional Injection of Bleomycin in the Treatment of Common Warts. Journal of Contemporary Medical Practice (JCMP), 2022; 4(5): 79-82.
• 13. Raj PAA, Pavulraj S, Kumar MA, Sangeetha S, Shanmugapriya R, et al. Therapeutic evaluation of homeopathic treatment for canine oral papillomatosis. Veterinary World 2020; 13(1): 206.
• 14. Kuntsi‐Vaattovaara H, Verstraete FJM, Newsome JT, Yuan H. Resolution of persistent oral papillomatosis in a dog after treatment with a recombinant canine oral papillomavirus vaccine. Veterinary and Comparative Oncology 2003; 1(1): 57-63.
• 15. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. British Journal of Dermatology 1996; 135(6): 969-971.
• 16. Bala N, Kumar A, Ranjan E, Gera V, Thombre R. Comparison of intralesional bleomycin versus salicylic acid 16.5% and lactic acid 16.5% combination paint in management of plantar warts. Medical Journal Armed Forces India, 2023.
• 17. Bianchi MV, Casagrande RA, Watanabe TT, Wouters AT, Wouters F, et al. Canine papillomatosis: a retrospective study of 24 cases (2001-2011) and immunohistochemical characterization. Pesquisa Veterinária Brasileira 2012; 32: 653-657.
• 18. Agnihotri D, Kushwah M, Kumar T, Kumar P, Kumar A, et al. Successful therapeutic management of a case of canine papillomatosis. The Haryana Veterinarian 2015; 54(1): 79–80.
• 19. Lira R, Lempek M, Marinho P, Neves C, Trombini HR. Use of Thuja occidentalis in the treatment of canine oral papillomatosis. Public Veterinary Journal 2012; 6(1): 16.
• 20. Miller W, Griffin C, Campbell K. Neoplastic and non neoplastic tumours. 7th ed. Muller and Kirk's Small Animal Dermatology. Missouri: Elsevier Mosby; 2013. pp. 774–778.
• 21. Biricik H, Cabalar M, Gulbahar M. Oral papillomatosis in a dog and its therapy with taurolidine. Acta Veterinaria Brno 2008; 77(3): 373–375.
• 22. Collier LL, Collins BK. Excision and cryosurgical ablation of severe periocular papillomatosis in a dog. Journal of the American Veterinary Medical Association 1994; 204(6): 881–883.
• 23. Stokking LB, Ehrhart EJ, Lichtensteiner CA, Campbell KL. Pigmented epidermal plaques in three dogs. Journal of the American Animal Hospital Association 2004; 40(5): 411–417.
• 24. Umadevi U, Saranya K, Mathi MP, Umakanthan T. Successful homeopathic treatment of transmissible tumour in dogs-case report. International Journal of Science and Research 2015; 4(4): 2799.
• 25. Ero U, Aihanuwa E, Clifford Nwabugwu A, Aimienwanlen OE, et al. Management of canine papillomatosis using oral acyclovir a case report. International Journal of Veterinary Science 2017; 6(4): 187–190.
• 26. Icen H, Sekin S, Simsek A, Kochan A, Tunik S. The efficacy of Tarantula cubensis extract (theranekron) in treatment of canine oral papillomatosis. Asian Journal of Animal and Veterinary Advances 2011; 6(7): 744–749.
• 27. Fantini O, Videmont E, Pin D. Successful treatment of florid papillomatosis in a dog using subcutaneous feline recombinant interferon-ω. Revue de Medecine Veterinaire 2015; 166(1-2): 25–29.
• 28. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, et al. Naturally occurring, non regressing canine oral papillomavirus infection:Host immunity, virus characterization and experimental infection. Virology 1999; 265(2): 365–374.
• 29. Saibaba M, Veena P, Vani G, Reddy KS, Kumar RVS. Clinical management of canine oral papillomatosis a case report. Scholars Journal of Agriculture and Veterinary Sciences 2016; 3(3): 249–250.
• 30. Megid J, Junior DJG, Aguiar DM, Junior GN, Silva WB, et al. Treatment of canine papillomatosis using Propionibacterium acnes. Arquivo brasileiro de medicina veterinária e zootecnia 2001; 53(5): 574–576.
• 31. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. The Journal of Antibiotics 1996; 19(5): 200-209
• 32. Bik L, Sangers T, Greveling K, Prens E, Haedersdal M, et al. Efficacy and tolerability of intralesional bleomycin in dermatology: a systematic review. Journal of the American Academy of Dermatology 2020; 83(3): 888-903.
• 33. Baeza-Hernández G, Cañueto J. Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma. Cancers 2024; 16(1): 158.
• 34. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617–624.
• 35. Fleischman RW, Baker JR, Thompson GR, Schaeppi UH, Illievski VR, et al. Bleomycin-induced interstitial pneumonia in dogs. Thorax 1971; 26(6): 675.
• 36. Thompson GR, Baker JR, Fleischman RW, Rosenkrantz H, Schaeppi UH, et al. Preclinical toxicologic evaluation of bleomycin (NSC 125 066), a new antitumor antibiotic. Toxicology and Applied Pharmacology 1972; 22: 544–555.
• 37. Kelly JM, Belding BA, Schaefer AK. Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin. Veterinary and comparative Oncology 2010; 8(2): 81-86.
• 38. Cooper JAD, Zitnik RJ, Matthay RA. Mechanisms of drug-induced pulmonary disease. Annual Review of Medicine 1988; 39: 395–404.
• 39. Saito F, Tasaka S, Inoue KI, Miyamoto K, Nakano Y, et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. American Journal of Respiratory Cell and Molecular Biology 2008; 38: 566–571. 40. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Annals of Oncology 2003; 14: 91–96.
• 41. Giuliano A, Almendros A. Retrospective Evaluation of a Combination of Carboplatin and Bleomycin for the Treatment of Canine Carcinomas. Animals 2022; 12(18): 2340.